Mela Sciences (NSDQ:Mela) said today that it agreed to purchased PhotoMedex‘s (NSDQ:PHMD) Xtrac and Vtrac laser business assets for $42.5 million. Xtrac and Vtrac are devices used to treat psoriasis, vitiligo and other skin diseases, the company said. “This is a transformational event for Mela Sciences. As a result of this acquisition, Mela becomes a multi-product […]
The market for aesthetic medical devices gained some ground during the 2nd quarter, a MassDevice.com analysis shows, although healthy sales growth didn’t necessarily translate into healthy bottom lines for all comers.
Biolase Technology (NSDQ:BLTI) CEO Federico Pignatelli agreed to another year at a $1 salary as the dental laser maker met Wall Street’s 4th-quarter forecast with a whopping 35% top-line bump.
Pignatelli set his annual pay package at $1 and 35,000 shares of BLTI stock when he took the role of vice chairman in July 2010, a month after he was terminated as president, SEC filings show.
News of the deal sent SYNO shares up nearly 49 percent to $27.78 from yesterday’s close. BAX shares ticked up 0.3 percent to $49.93 as of about noon today.
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Medtronic Inc. (NYSE:MDT) said results from the Improve HF study demonstrate that select guideline-based outpatient heart failure measures can increase patient survival and might be useful for improving patient quality of care.
The Improve HF (The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting) study is the largest U.S.-based outpatient heart failure clinical study. The results of the study were published in the journal Circulation.